URGN
UroGen Pharma Ltd.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 3 ▼ 2 insiders sell $292.4K at $19.69
- May 8 ▼ 1 insider sell $300.0K at $30.00
- Jun 8 ▼ 1 insider sell $142.6K at $27.30
- Jun 22 ▼ 1 insider sell $350.1K at $35.01
- Jul 9 ▼ 1 insider sell $400.0K at $40.00
- Aug 20 ▼ 1 insider sell $2.9M at $47.05
- Sep 8 ▼ 2 insiders sell $102.0K at $42.68
- Sep 30 ▲ 4 funds open new positions (13F)
- Oct 8 ▼ 1 insider sell $80.8K at $36.69
- Oct 15 ▲ Short interest falls 27.8% to 5.61M
- Nov 2 FDA: UroGen Announces First Patient Dosed in Phase 1 Trial of U…
- Nov 4 ▼ ZUSDURI revenue grew 35% QoQ to $68.0M, but JELMYTO revenue declined…
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $4.5M.
- InstitutionsBULLISH
Q3 2026: 33 added (4 new), 11 trimmed or exited. Largest new: Ing Groep Nv $91.7M, Walleye Capital $14.1M.
- AnalystsBULLISH
12 of 13 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate $0.390 → $0.448 over 90 days. 5 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest −8.9% to 5.11M shares. 5.1 days to cover, ≈10.4% of shares.
- TrendDOWNTREND
23% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| ING GROEP NV | NEW | $91.7M |
| Walleye Capital LLC | NEW | $14.1M |
| FEDERATED HERMES, INC. | DOUBLED | $12.4M |
| Qube Research & Technologies Ltd | NEW | $11.7M |
| UBS Group AG | DOUBLED | $10.8M |
| Nuveen, LLC | DOUBLED | $9.8M |
| JPMORGAN CHASE & CO | DOUBLED | $8.5M |
| Russell Investments Group, Ltd. | ADD | $7.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
13 analystsPrice is below the lowest target. Median implies +114%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 5, 2026 | Guggenheim MAINTAIN | Buy |
| Oct 19, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 6, 2026 | Guggenheim MAINTAIN | Buy |
| Aug 6, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Aug 5, 2026 | TD Cowen MAINTAIN | Buy |
| Jul 21, 2026 | Guggenheim MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Degnan Chris Chief Financial Officer Oct 8, 2026 | EXERCISE | 4,483 sh |
Degnan Chris Chief Financial Officer Oct 8, 2026 | SELL | $80.8K |
Smith Jason Drew General Counsel Sep 8, 2026 | SELL | $64.6K |
Schoenberg Mark Chief Medical Officer Sep 8, 2026 | SELL | $37.4K |
Smith Jason Drew General Counsel Sep 7, 2026 | EXERCISE | 3,334 sh |
Schoenberg Mark Chief Medical Officer Sep 7, 2026 | EXERCISE | 1,667 sh |
Robinson James A. Jr. Director Aug 26, 2026 | EXERCISE | 2,000 sh |
Schoenberg Mark Chief Medical Officer Aug 20, 2026 | SELL | $2.9M |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.45 | $0.13–$0.66 | +15.0% | $107.1M |
| Next Q | $0.32 | $0.01–$0.68 | -23.6% | $114.5M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
12 filings · 4 press releases · 2 bullish · 1 bearish · 9 neutral- NEUTRAL SC 13G/ANov 13, 2026
Toronto Dominion Bank filed an amended Schedule 13G disclosing a reduced passive stake in UroGen…
A passive holder reducing its stake is routine and not a signal of changing fundamentals. Monitor next 13F for broader institutional positioning trends, but this filing alone does not indicate a…
- NEUTRAL 8-KNov 4, 2026
UroGen reported Q3 2026 total revenue of $89.0M, up from $27.5M a year ago, driven by ZUSDURI net…
ZUSDURI's 35% QoQ growth and narrowing net loss signal strong commercial execution, but the JELMYTO guidance cut and cash burn ($17.5M QoQ decline in cash) temper the positive read. The UGN-103…
- BEARISH PRESS-RELEASENov 4, 2026
ZUSDURI revenue grew 35% QoQ to $68.0M, but JELMYTO revenue declined to $21.0M and full-year…
The EPS miss and JELMYTO guidance cut are the primary negatives, partially offset by ZUSDURI growth and UGN-103 NDA acceptance. Watch for UGN-103 PDUFA decision in June 2027 and any updates on the…
- NEUTRAL PRESS RELEASENov 2, 2026
UroGen Pharma announced the first patient dosed in a Phase 1 trial of UGN-501, a next-generation…
This is a very early clinical milestone with no efficacy data. The absence of RTGel in the current formulation means the Phase 1 results may not reflect the potential of the RTGel-formulated…
All URGN filing & press-release reports (16)
- SC 13G/A reportNov 13, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- PRESS-RELEASE reportNov 2, 2026
- SC 13G/A reportOct 27, 2026
- PRESS-RELEASE reportOct 19, 2026
- 144 reportOct 9, 2026
- CLUSTER reportSep 9, 2026
- 8-K reportAug 20, 2026
- 8-K reportAug 5, 2026
- 8-K reportJun 23, 2026
- 8-K reportJun 2, 2026
- PRESS-RELEASE reportMay 6, 2026
- PRESS-RELEASE reportApr 29, 2026
- PRESS-RELEASE reportMar 2, 2026
- PRESS-RELEASE reportMar 2, 2026